Search results
'Oppenheimer' Cinematographer Says Big Movies Belong on Big Screens, Not Netflix
TMZ· 2 days agoAcclaimed cinematographer Hoyte van Hoytema disagrees with Netflix CEO Ted Sarandos' stance that...
'It' Gets a Prequel Series: Everything to Know About 'Welcome to Derry'
Parade via AOL· 11 hours agoHe's also appeared in Once Upon a Time...In Hollywood, X-Men: First Class, Pineapple Express, Horns...
Oppenheimer raises Utilities sector rating, cuts Real Estate By Investing.com
Investing.com· 7 days agoOppenheimer analysts raised their rating for the utilities sector and cut the rating for real estate...
Keeping an Eye on Under Armour Inc
Knox Daily· 13 hours agoIn the meantime, Oppenheimer downgraded its Under Armour Inc [UAA] rating to a Perform from a an Outperform in a research note published recently. A number of analysts have ...
Goldman’s Oppenheimer Says Stock Rally to Stall on Rising Yields
Bloomberg via Yahoo Finance· 5 days ago(Bloomberg) -- The powerful rally in stocks this year is likely to fizzle out as a rise in bond...
Oppenheimer's Stoltzfus Says S&P Could Top 5,500 by Year-End
Bloomberg· 4 days agoOppenheimer's John Stoltzfus says the S&P 500 could top 5,500 by the end of the year. He says...
Netflix movie of the day: Godzilla Minus One is one of the best films of the last year, and it just...
TechRadar· 17 hours agoGodzilla Minus One arrived last year with phenomenal word-of-mouth, and I personally ranked it as my...
Oppenheimer maintains 'Outperform' on CATX with $2 target By Investing.com
Investing.com· 4 days agoOn Thursday, Oppenheimer reiterated an Outperform rating on Perspective Therapeutics Inc (NYSE:CATX)...
Netflix CEO sees no reason why Barbie and Oppenheimer wouldn't have been just as big on Netflix
Games Radar· 7 days agoTed Sarandos has shared his thoughts on Barbenheimer – and he thinks both films could've been as big...
Biomea Fusion (NASDAQ:BMEA) Price Target Cut to $60.00 by Analysts at Oppenheimer
ETF DAILY NEWS· 4 days agoBiomea Fusion (NASDAQ:BMEA – Free Report) had its price objective lowered by Oppenheimer from $70.00 to $60.00 in a report published on Thursday morning, Benzinga reports.